

國立臺灣大學醫學院免疫所

碩士論文

Graduate Institute of Immunology

College of Medicine

National Taiwan University

Master Thesis



DAPK 抑制 T 細胞中 PKC θ 活化機轉之研究

Study on how DAPK inhibits the activation of PKC θ in T cells

研究生：張沛昀

Graduate Student : Pei-Yun Chang

指導教授：賴明宗博士

Advisor : Ming-Zong Lai, Ph.D.

中華民國 102 年 6 月

June, 2013

國立臺灣大學碩士學位論文
口試委員會審定書

DAPK 抑制 T 細胞中 PKC θ 活化機轉之研究
Study on how DAPK inhibits the activation of PKC θ in T cells

本論文係張沛昀君（學號 R00449011）在國立臺灣大學醫學院免疫學研究所完成之碩士學位論文，於民國 102 年 06 月 27 日承下列考試委員審查通過及口試及格，特此證明

口試委員：

張明宇

（簽名）

（指導教授）

張希楨

李秀香

系主任、所長 江伯倫

誌謝



兩年的研究生活真是轉眼間就結束了，在這期間最要感謝的是賴明宗老師，老師總是很有耐心地跟我討論實驗上及生活上的各種問題，並且以身作則地展示了科學家的面貌；每次和老師聊天之後，都有各種層面的提升。謝謝繆希椿老師對於論文的指導及細節的要求，使我在撰寫論文的時候具備嚴謹的態度；也謝謝繆老師在 seminar 課程當中的帶領，讓我們全班都很努力地發問，並且學到很多求知的正確態度。謝謝李秀香老師的指導，不僅在論文方面很仔細地與我討論並且給予許多建議，也關心並傾聽我未來的規劃，使我獲益良多。

在這兩年忙碌的研究生活以來，非常感謝中研院分生所 503 實驗室的大家。最要感謝定芳學長，一直以來教導我做實驗，並且時常與我討論 paper 及做科學的正確態度；學長並且身兼領頭羊一職，帶領我們勇往直前迎向未來。謝謝雅婷學姊，在兩年前教導我許多實驗，帶我進入科學的世界。謝謝明仙學姊時常跟我分享實驗及生活上的事情，給我許多長輩的建議。謝謝妍庭學姊做為大家的後盾，並且帶領我進入肚皮舞的世界。謝謝惠文學姊在實驗方面的幫忙，學姊做實驗的嚴謹態度給我很大的正面影響。謝謝育堦學長、泳萱學姊、子勝學長，一直以來給予我許多實驗上的寶貴意見。謝謝禹蓉學姊的樂觀態度及實驗的建議，給我許多正面的力量。謝謝琬甄學姊在實驗上及生活上的所有協助，每次討論完實驗後總會豁然開朗，雖然 data 不一定會開朗地出現就是了。謝謝舒婷，每天一起大量地做實驗及小量地玩樂，並且很辛苦地處理實驗室的大小瑣事，舉辦紓壓活動，讓我們都可以安心地做實驗，真是新時代的好女性。謝謝筱庭一路的扶持，現在終於要一起畢業了，賣三頓的老闆娘一定很欣慰。謝謝雨蓉來到我們實驗室成為小雨蓉，一起買早餐然後衝刺 212 的往事真是歷歷在目，你模仿 T cell 活化的表演我會永生難忘的。謝謝早餐日，謝謝甜點日以及生日的不成文規定，使我這兩年當中即使非常忙碌也不會消瘦。


謝謝免疫所的所有老師，兩年來的課程讓我有許多收穫。比起大學部時期，學習了許多更加深入且精闢的理論。謝謝純菁助教，總是不厭其煩地提醒我們填寫許多文件，在我們系學會舉辦活動的時候更是大力支持。謝謝士鈺，雖然我們聚少離多，但是妳的冷笑話還是常常讓我驚訝，所以才會不小心輕拍妳的手臂。謝謝乃如，跟你做鄰居真是太好了，我們還有幾家 brunch 沒吃以及 ice monster 都要好好規劃一下。謝謝孟萍，剛才差點打成米酒，謝謝妳幫我們特訓羽球，還有妳高超的騎車技術真是太令我羨慕了。謝謝鈺琪，時常收留我們的雜物，每個禮拜一起吃飯真是太開心了。謝謝宛蓉，一起吃飯分享實驗的心得真的收穫很多，尤其我們還一起經歷過公車痴漢事件。謝謝于婷，騎車真的要小心喔，看妳健康

又快樂地順利完成厲害的研究真是太棒了。謝謝子軒，身為康樂股長真是十分稱職，一起舉辦活動以及玩樂真是太開心了。謝謝琮皓，你半夜打卡常常讓我感到溫馨，但是騎車一定要小心身體。謝謝宗霖，雖然許多活動你都無法參加實在可惜，但是以後還有很多機會的。謝謝高高高賢能，雖然你身為系學會會長好像有點辛苦，但又好像蠻輕鬆的。謝謝冠雄，希望你早日找到意中人，然後繼續深造好像也不錯。

謝謝盈秀、孟萱、書仔、政穎、昀真、成懋、才雄、旻志，時常一起揪團唱歌吃飯玩樂。謝謝學君、儀婷、沁羽、鈺珊、林宜，老姊妹們一起談天說地互相依靠真是太幸福了。謝謝雅筑(養豬)時常噓寒問暖，在我一生中給我很大的支持。謝謝婷雅跟阿白，即使我們分隔兩地，但我相信你們是人在倫敦心在台。謝謝懷恩、閔宜、佩君、伊琳、以璇，老朋友互相陪伴真好。謝謝盛琪、承祐，一起吃飯聊天大笑關懷金融新趨勢。謝謝芷菱、思瑜陪我一起上健身房運動，讓我發胖不會太明顯。謝謝愛我的爸媽弟妹及親戚們，一直關懷著我的身體、年齡及收入，在我快樂或失意的時候都給我很大的支持。謝謝親愛的李佳燁，在你出國讀書的這段日子以來，每天都鼓勵我幫助我叫我起床，雖然一起在不同的城市努力，但是心都一直靠得很近。

謝謝所有人的幫忙，希望我有一天也能幫助更多的人。

摘要




DAPK 是一個已知的抑癌蛋白。實驗室先前的研究發現，DAPK 能在 T 細胞受體刺激之下活化，並且藉由抑制 NF- κ B 路徑而阻礙 T 細胞活化。在更進一步的研究中指出，DAPK 只會特定地抑制由 T 細胞受體所引發的 NF- κ B 活化，並不影響 TNF α 或 IL-1 β 所引發的 NF- κ B 活化。DAPK 抑制 T 細胞受體所引發的 NF- κ B 活化是透過影響 T 細胞受體所引發的 PKC θ 磷酸化；然而，DAPK 抑制 PKC θ 活化過程的機制目前仍然未被探討。在本研究中，我們探討 DAPK 如何抑制 T 細胞受體所引發的 PKC θ 磷酸化。最近的研究中指出，MAP4K3/GLK 是在 T 細胞受體活化之下，負責磷酸化 PKC θ 的激酶。我們發現在 HEK293T 細胞及 Jurkat T 細胞之中，DAPK 與 PKC θ 及 MAP4K3/GLK 皆具有交互作用。我們也發現 DAPK 與 PKC θ 及 MAP4K3/GLK 之間會以許多不同蛋白區位進行交互作用。在體外激酶實驗中，我們發現 DAPK 並不會磷酸化 PKC θ 及 MAP4K3/GLK，但是 DAPK 會抑制 MAP4K3/GLK 活化所必需的自體磷酸化作用及其激酶活性。有研究指出，T 細胞受體所引發的 MAP4K3/GLK 活化過程必須經過 SLP-76 與 MAP4K3/GLK 進行交互作用才能達成。我們發現在 HEK293T 細胞及 Jurkat T 細胞之中，DAPK 與 SLP-76 具有交互作用。在免疫沉澱實驗中，我們發現 DAPK 抑制 SLP-76 與 MAP4K3/GLK 在 T 細胞受體刺激之下所引發的交互作用。我們的結果顯示 DAPK 可能是利用不同的機制調控 T 細胞受體刺激所引發的 PKC θ 活化，一是透過降低 MAP4K3/GLK 激酶的活性，二是藉由抑制 MAP4K3/GLK 與上游鷹架蛋白 SLP-76 之間的連結而使 MAP4K3/GLK 無法活化，進而間接抑制其下游受質 PKC θ 的活化。DAPK 如何抑制 T 細胞受體刺激所引發的 NF- κ B 訊息，並專一性抑制 PKC θ 活化之詳細機制尚待更進一步的實驗探討。

Abstract



Death-associated protein kinase (DAPK) is well known as a tumor suppressor. Previous studies from our lab have shown that DAPK is activated after TCR stimulation. DAPK inhibits T cell activation through suppression of NF- κ B signaling. Furthermore, DAPK specifically inhibits the TCR-induced NF- κ B activation but not TNF α - or IL-1 β -induced NF- κ B activation. Results from our lab also demonstrated that DAPK inhibits TCR-induced PKC θ phosphorylation, but the exact biochemical process targeted by DAPK to inhibit PKC θ activation remains unclear. The specific aim of this study is to delineate the molecular mechanism on how DAPK inhibits TCR-induced PKC θ phosphorylation. MAP4K3/GLK is recently identified as the kinase that phosphorylates and activates PKC θ after TCR stimulation. We found that DAPK interacted with both PKC θ and MAP4K3/GLK in HEK293T cells and Jurkat JE6.1 T cells. We also identified several domains of DAPK that mediate the binding to PKC θ and MAP4K3/GLK. Using *in vitro* kinase assay, we found that DAPK did not phosphorylate PKC θ . DAPK did not phosphorylate MAP4K3/GLK, but DAPK inhibited MAP4K3/GLK auto-phosphorylation and kinase activity. We also found that DAPK bound SLP-76, the adaptor protein which binds MAP4K3/GLK and is required for MAP4K3/GLK activation. *In vitro* binding analysis demonstrated that the presence of DAPK decreased the binding between SLP-76 and MAP4K3/GLK.

DAPK also inhibited the association between SLP-76 and MAP4K3/GLK in Jurkat JE6.1 T cells. Therefore, DAPK uses at least two different mechanisms to inhibit TCR-induced PKC θ activation: one by suppressing MAP4K3/GLK kinase activity, the other by reducing the binding of MAP4K3/GLK to SLP-76. Further characterization on the processes underlying the inactivation of MAP4K3/GLK and the reduced association of MAP4K3/GLK-SLP-76 by DAPK may help to understand the exact inhibitory mechanism of DAPK in TCR-induced NF- κ B signaling.




List of Abbreviations




BSA	Bovine serum albumin
CaM	Calmodulin
Bisacrylamide	N', N'-Methylene bisacrylamide
CCLR	Culture cell lysis reagent
DAPK	Death-associated protein kinase
DMEM	Dulbecco's modified eagle medium
ECL	Enhanced chemiluminescence
EDTA	Ethylene diaminetetraacetic acid
FBS	Fetal bovine serum
HA	Hemagglutinin
His	Histidine
IB	Immunoblot
IP	Immunoprecipitation
IPTG	Isopropyl β -D-1-thiogalactopyranoside
LAR	Luciferase assay reagent
MAP4K3/GLK	Germinal center kinase-like kinase
MBP	Myelin basic protein
MLC	Myosin light chain
NF- κ B	Nuclear factor kappa beta
PBS	Phosphate buffered saline
PCR	Polymerase chain reaction
PKC θ	Protein kinase C θ
PMSF	Benzylsulfonyl fluoride

SLP-76	Src homology 2 (SH2) domain-containing leukocyte protein of 76 kDa
SDS-PAGE	Sodium dodecyl sulfate polyacrylamide gel electrophoresis
TCR	T cell receptor
WCE	Whole cell extract



Content



口試委員會審定書.....	i
致謝.....	ii
摘要.....	iv
Abstract.....	v
List of Abbreviations.....	vii
Content.....	1
Chapter I Introduction.....	5
1.1 Death-associated protein kinase (DAPK).....	5
1.2 T cell activation.....	6
1.2.1 The signal transduction of T cell activation.....	6
1.2.2 Src homology 2 (SH2) domain-containing leukocyte protein of 76 kDa (SLP-76).....	8
1.2.3 Germinal center kinase-like kinase (MAP4K3/GLK).....	9
1.2.4 Protein kinase C θ (PKC θ).....	10
1.2.5 DAPK inhibits T cell activation at the stage on or upstream of PKC θ ...	11
1.3 Rationale.....	12
Chapter II Materials and Methods.....	13
2.1 Cell lines and cell culture.....	13
2.1.1 Cell lines.....	13
2.1.2 Cell culture.....	13
2.2 Antibodies.....	13
2.3 Chemicals and reagents.....	14
2.4 Plasmid construction and preparation.....	15
2.4.1 Construction of pcDNA4-hPKC θ -6xHA.....	15
2.4.2 Construction of pcDNA4-hMAP4K3/GLK-myc.....	15
2.4.3 Construction of pcDNA4-hMAP4K3/GLK-6xHA.....	16
2.4.4 Construction of truncated forms of human MAP4K3/GLK.....	16

2.4.5 Construction of pcDNA4-hSLP-76-6xHA.....	17
2.4.6 Construction of kinase-dead form of human PKC θ	17
2.4.7 Construction of kinase-dead form of human MAP4K3/GLK.....	18
2.5 Transfection of plasmid DNA.....	18
2.5.1 Calcium phosphate transfection.....	18
2.5.2 Retrovirus infection.....	19
2.5.3 Electroporation.....	19
2.6 T cell activation.....	19
2.7 Western Blotting.....	20
2.8 Immunoprecipitation.....	20
2.9 Luciferase assay.....	21
2.10 <i>In vitro</i> kinase assay.....	22
2.11 <i>In vitro</i> binding assay.....	22
Chapter III Results.....	23
3.1 Establishment of Jurkat JE6.1 T cell line stably expressing DAPK.....	23
3.2 DAPK inhibits TCR-stimulated NF- κ B activation.....	23
3.2.1 Expression of DAPK mutant forms affects the activation of NF- κ B reporter.....	23
3.2.2 DAPK suppresses TCR-induced phosphorylation of PKC θ	24
3.3 Interaction of DAPK with PKC θ	24
3.3.1 Immunoprecipitation analysis of DAPK and PKC θ	24
3.3.2 Determination of the interaction domains between DAPK and PKC θ ..	25
3.4 Interaction of DAPK with GLK.....	25
3.4.1 Immunoprecipitation analysis of DAPK and GLK.....	25
3.4.2 Determination of the interaction domains of DAPK and GLK.....	26
3.5 To determine whether PKC θ or GLK is the substrate of DAPK.....	27
3.5.1 Preparation of human PKC θ recombinant protein.....	27
3.5.2 Preparation of human GLK recombinant protein.....	27
3.5.3 Kinase assay performed with DAPK and PKC θ	27
3.5.4 Preparation of PKC θ and GLK kinase-dead recombinant proteins.....	28
3.5.5 DAPK does not phosphorylates PKC θ <i>in vitro</i>	28
3.5.6 DAPK does not phosphorylates GLK <i>in vitro</i>	29
3.6 To determine whether DAPK affect the kinase activity of GLK.....	29
3.6.1 Kinase assay performed with GLK and MBP.....	29
3.6.2 Preparation of human GLK recombinant protein.....	30
3.6.3 Kinase assay performed with MAP4K3/GLK and SLP-76.....	30
3.7 To determine whether DAPK interferes with the association of GLK and	

SLP-76.....	31
3.7.1 DAPK interacts with SLP-76.....	32
3.7.2 The endogenous GLK-SLP-76 association is reduced by DAPK.....	32
3.7.3 DAPK inhibits the in vitro binding between GLK and SLP-76.....	32
Chapter IV Discussion.....	34
4.1 DAPK is associated with SLP-76, MAP4K3/GLK, and PKC θ	34
4.2 DAPK kinase activity and inhibition of NF- κ B activation.....	35
4.3 DAPK inhibits the kinase activity of MAP4K3/GLK.....	35
4.4 DAPK inhibits the association of MAP4K3/GLK and SLP-76.....	36
Chapter V Reference.....	38
Chapter VI Figures.....	40
Figure 1. Over-express DAPK in Jurkat JE6.1 T cell.....	40
Figure 2. DAPK inhibits TCR-stimulated NF- κ B activation.....	41
Figure 3. DAPK inhibits TCR-stimulated PKC θ phosphorylation.....	42
Figure 4. Interaction of DAPK with PKC θ in HEK 293T cell.....	43
Figure 5. Interaction of DAPK with PKC θ in Jurkat JE6.1 T cell.....	44
Figure 6. The interaction between DAPK and PKC θ is mediated by multiple domains.....	45
Figure 7. The interaction between PKC θ and DAPK is mediated by multiple domains.....	46
Figure 8. Interaction of DAPK with GLK in HEK 293T cell.....	47
Figure 9. Interaction of DAPK with GLK in Jurkat JE6.1 T cell.....	48
Figure 10. The interaction between DAPK and GLK is mediated by multiple domains.....	49
Figure 11. The interaction between GLK and DAPK is mediated by multiple domains.....	50
Figure 12. Generation of the recombinant protein of PKC θ	51
Figure 13. Generation of the recombinant protein of GLK.....	52
Figure 14. Auto-phosphorylation of PKC θ	53
Figure 15. Generation of the kinase-dead recombinant protein of GLK and PKC θ	54
Figure 16. PKC θ is not a substrate of DAPK.....	55
Figure 17. GLK is not a substrate of DAPK.....	56
Figure 18. The presence of DAPK reduces the kinase activity of GLK to MBP...	57
Figure 19. Generation of the recombinant protein of SLP-76.....	58

Figure 20. The presence of DAPK reduces the kinase activity of GLK to SLP-76.....	59
Figure 21. Interaction of DAPK with SLP-76.....	60
Figure 22. The association of GLK and SLP-76 is attenuated by DAPK in Jurkat JE6.1 T cells.....	61
Figure 23. The association of GLK and SLP-76 is inhibited by DAPK in vitro....	62
Figure 24. Model on DAPK-mediated inhibition of PKC θ activation.....	63
Chapter VII Appendix.....	64
Appendix 1. DAPK protein structure.....	64
Appendix 2. DAPK family.....	65
Appendix 3. PKC θ protein structure.....	66
Appendix 4. GLK protein structure.....	67
Appendix 5. Signal transduction of TCR-induced T cell activation.....	68
Appendix 6. NF- κ B pathway.....	69
Appendix 7. Diagram of GLK-induced PKC θ /NF- κ B activation during TCR signaling.....	70
Appendix 8. pET-21a map.....	71
Appendix 9. pcDNA4/6xHA map.....	72
Appendix 10. κ B-Luc schematic diagram.....	73

Chapter I Introduction




1.1 Death-associated protein kinase (DAPK)

Death-associated protein kinase is a tumor suppressor, and its expression is downregulated in many cancer types. DAPK was identified from the γ -interferon induced cell death in HeLa cells, where DAPK is one of the positive regulators[1]. Further evidences have shown that DAPK is required for cell death induction by various death signals.

DAPK is a 160 kDa protein with multiple domains, and the kinase domain locates at the N-terminus part of the protein. Like other kinds of CaM kinases, the kinase domain is followed by a calcium/calmodulin regulatory domain, which acts as a pseudo-substrate to suppress catalytic activity by binding to the kinase region[2, 3]. Upon the binding of Ca^{2+} to calmodulin, the affinity between calcium/calmodulin regulatory domain and kinase domain is reduced, which results in the activation of DAPK. The calcium/calmodulin regulatory domain-deleted form of DAPK, DAPK- Δ CaM, acts as a constitutively active kinase. In contrast, with the mutation of a conserved lysine in the kinase domain to alanine, DAPK-K42A, loses kinase activity and acts as a dominant negative form of DAPK[4]. The kinase activity of DAPK is affected by additional posttranslational modifications. The

auto-phosphorylation of Ser308 located in calcium/calmodulin regulatory domain interferes with the activation of DAPK[3].




The ankyrin repeats and the death domain at C-terminus of DAPK interact with other proteins to transduce signals. The cytoskeleton domain of DAPK serves to bind to cytoskeleton. The function of P-loop motif of DAPK is still not clear.


1.2 T cell activation

1.2.1 The signal transduction of T cell activation

T cells are a subset of lymphocytes that play essential roles in the cell-mediated immunity. The activation of T cells leads to clonal expansion and differentiation. Upon the engagement of T cell receptor and MHC-antigenic peptide complex presented by antigen presenting cells, the Src family PTKs (protein tyrosine kinases) will be activated by CD45 tyrosine phosphatase. The activated Src PTKs then phosphorylate the tyrosine residue at immunoreceptor tyrosine-based activation motifs (ITAMs) on CD3 ϵ , CD3 δ , CD3 γ and CD3 ζ subunits of T cell receptor complex[5, 6]. Following the phosphorylation of ITAMs on T cell receptor, another Syk family PTK, ZAP-70 (ζ -associated protein of 70kDa), is recruited to bind to the phosphorylated ITAMs within its SH2 (Src-homology 2) region. ZAP-70 is phosphorylated by Src PTKs to become active. ZAP-70 phosphorylates adaptor



protein LAT (linker for activation of T cells), and the phosphorylated LAT links a variety of adaptor proteins and enzymes to form a signalosome for transducing activation signals[7-9]. ZAP-70 also phosphorylates and activates SLP-76 (SH2 domain containing leukocyte protein of 76kDa)[5]. PLC- γ 1, Grb2 and Gads are recruited to specific phosphorylated tyrosines on LAT. SLP-76 is then become associated with LAT through binding to Gads. SLP-76 accommodates Itk, and Itk phosphorylates the PLC- γ 1 within signalosome. The activated PLC- γ 1 is responsible for hydrolyzing phosphatidylinositol-4,5-bisphosphate (PIP₂) in the plasma membrane into second messengers diacylglycerol (DAG) and inositol 1,4,5-triphosphate (IP₃)[5]. After the cleavage, DAG activates numbers of proteins, including different isoforms of PKC (protein kinase C), for further downstream signal transduction. Another second messenger, IP₃, stimulates the efflux of Ca²⁺ from endoplasmic reticulum to the cytosol and the influx of Ca²⁺ from outside of the cell[10]. As a result, increased Ca²⁺ binds calmodulin and leads to the activation of calcineurin, which consequently dephosphorylates nuclear factors of activated T-cells NF-AT1 (NFATc2 or NFATp), NF-AT2 (NFATc1 or NFATc), NF-AT3 (NFATc4) and NF-AT4 (NFATc3). The dephosphorylated NFATs are then translocated into the nucleus, where they cooperate with other transcription factors and promote the transcription of specific genes[11, 12].




The binding of phosphorylated LAT to adaptor protein Grb2 results in recruitment of SOS (Son of sevenless homolog 1 and 2), SOS in turns activates H-Ras (v-Ha-Ras Harvey rat sarcoma viral oncogene homolog). Ras activation leads to sequential activation of c-Raf-1 (v-Raf-1 murine leukemia viral oncogene homolog 1), MEK1/2 (mitogen-activated protein kinase 1/2 and ERK1/2 (mitogen-activated protein kinases 1/2. The phosphorylated ERK1/2 enter the nucleus and activate the c-Fos, and the activated JNK phosphorylates c-Jun. c-Fos and c-Jun are dimerized in the nucleus to form the transcription factor AP-1 (activator protein 1).

Together with the activation of NF- κ B, transcription factors NFAT and AP-1 serve to turn on the gene expression of IL-2 and other kinds of cytokines, leading to the growth and differentiation of T cells[13].

1.2.2 Src homology 2 (SH2) domain-containing leukocyte protein of 76 kDa (SLP-76)

SLP-76 is an adaptor protein originally identified as a downstream substrate of ZAP-70. TCR engagement leads to ZAP70, then phosphorylates SLP-76 and LAT. Activated LAT recruits SLP-76 to the membrane, where LAT and SLP-76 nucleate a complex composed of the guanine-nucleotide-exchange factor VAV, PLC γ 1, non-catalytic region of tyrosine kinase (NCK), TEC-family kinase interleukin T-cell




kinase (ITK), adhesion- and degranulation-promoting adaptor protein (ADAP) and haematopoietic progenitor kinase 1 (HPK1)[14]. SLP-76 has three distinct domains. NH2-terminal domain is rich in tyrosine residues. Phosphorylated tyrosine residues bind SH2-domain containing proteins such as Vav, Nck and the Tek kinase ITK [15-17]. The central proline-rich domain binds to SH3-domain containing proteins that include PLC γ 1 and Gads. The C-terminal SH2 domain associates with haematopoietic progenitor kinase 1 (HPK1) and adhesion- and degranulation-promoting adaptor protein (ADAP)[18].

SLP-76 is essential for thymocyte development. SLP-76 is involved in the signaling pathway initiated by TCR engagement. Recent study indicated that SLP-76 is a crucial adaptor protein in the TCR-induced PKC θ activation[19].

1.2.3 Germinal center kinase-like kinase (MAP4K3/GLK)

The conserved serine/threonine-specific protein kinase, germinal center kinase-like kinase (GLK, also termed MAP4K3), belongs to the ste20-like serine/threonine kinases family, which serve to respond to the extracellular stimuli and regulate a number of gene transcription, cell mitosis, cell differentiation, cell apoptosis and immune inflammation[20, 21]. Recent study reveals that MAP4K3/GLK directly activates PKC θ in the TCR signaling-induced T cell

activation[19]. Furthermore, the enhanced expression of MAP4K3/GLK is shown to be involved in autoimmune disease such as systemic lupus erythematosus[21].



1.2.4 Protein kinase C θ (PKC θ)


Protein kinase C (PKC) is a family of serine/threonine specific protein kinases. The PKC family consists of fifteen isoforms in humans [22], and can be divided into three groups. The first group of PKC family is Ca^{2+} -dependent type, containing PKC α , PKC β and PKC γ . The second group of PKC family is Ca^{2+} -independent type, containing PKC δ , PKC ϵ , PKC η , PKC θ and PKC μ . The third group of PKC family is unconventional type, containing PKC ζ and PKC ι/λ [23]. PKC θ belongs to the Ca^{2+} -independent type conventional PKC, in which the activation requires DAG but not Ca^{2+} . In the activation of T cells, PKC θ is localized in the cSMAC (central region of the supra-molecular activation complex) of the immunological synapse formed by T cells and APC, suggesting that PKC θ plays an essential role in the T cell activation [24]. SLP-76 is important for recruiting PKC θ . Activated PKC θ phosphorylates CARMA1 and enhances the formation of complex composed of Bcl-10, MALTI and CARMA1, leading to activation of the IKK complex, followed by I κ B protein to undergo phosphorylation and degradation. The transcription factor NF- κ B will be translocated into nucleus and hence activate the expression of specific downstream

genes [25].


In addition to regulating the T cell activation, PKC θ is also important for promoting the viability of T cells. By activating the NF- κ B pathways, PKC θ induces the expression of Bcl-2, Bcl-xL and c-FLIP, the critical anti-apoptotic molecules. In addition, PKC θ directly phosphorylates BAD and inactivates BAD, a pro-apoptotic protein, to promote the viability of T cells [13].

1.2.5 DAPK inhibits T cell activation at the stage on or upstream of PKC θ

While DAPK is a well-known tumor suppressor, the role it plays in the T cell activation is barely defined. Previous studies from our lab have shown that after TCR stimulation, DAPK is activated immediately. DAPK inhibits T cell activation through down-regulating the NF- κ B pathway. Furthermore, DAPK specifically inhibits the TCR-induced NF- κ B activation but not TNF α - or IL-1 β -induced NF- κ B activation. Results from our lab also demonstrated that DAPK inhibits the phosphorylation of PKC θ [13], but whether DAPK targets to PKC θ or a step upstream of PKC θ remains unclear. In this study, our goal is to investigate how DAPK inhibits the phosphorylation of PKC θ , based on recent identification that MAP4K3/GLK directly activates PKC θ [19].



1.3 Rationale



DAPK negatively regulates TCR-induced PKC θ phosphorylation. A logic first step to delineate the mechanism of inhibition is to investigate whether DAPK directly phosphorylates and inactivates PKC θ . Based on the direct phosphorylation of PKC θ by MAP4K3/GLK, we will also examine whether DAPK affects PKC θ activation through direct phosphorylation and inhibition of MAP4K3/GLK. We will also explore the potential interaction between DAPK, MAP4K3/GLK and PKC θ in HEK293T cells, and in Jurkat JE6.1 T cells expressing DAPK.

The specific aims of the present study are:

- (1) To investigate whether DAPK inhibits TCR-induced PKC θ activation through direct phosphorylation and inhibition of PKC θ .
- (2) To determine whether DAPK suppresses PKC θ activation through direct phosphorylation and inhibition of MAP4K3/GLK.
- (3) To delineate the exact biochemical mechanism for the inhibition of PKC θ or MAP4K3/GLK by DAPK.

Chapter II Materials and Methods



2.1 Cellines and cell culture

2.1.1 Cell lines

Jurkat E6.1 is human T lymphoma cells. EL4 is mouse thymus lymphoma cells.


HEK293T is primary human embryonic kidney cells transfected with SV40 large T antigen. 293 Phoenix cell is transformed human kidney cells that express proteins essential for retroviruses, the cell line is derived from Dr. Garry Nolan (Stanford University, CA).

2.1.2 Cell culture

Jurkat E6.1 cell and EL4 cell were cultured in completed RPMI 1640 with 5% FBS, 10 μ M L-glutamine, 10 unit/ml Penicillin/streptomycin and 20 mM β -Mercaptoethanol, and incubated in 5% CO₂ incubator at 37°C. HEK293T cell and 293 Phoenix cell were cultured in 10% FBS contained DMEM medium in 5% CO₂ incubator at 37°C.

2.2 Antibodies


Anti-DAPK antibody (clone DAPK-55), anti-MAP4K3/GLK antibody (766-780) and anti-Flag-M2 antibody were purchased from Sigma (St. Louis, MO). Anti-PKC θ antibody (clone C-19), anti-SLP-76 antibody (clone H-300), anti-MBP (clone C-16)



and anti-PLC- γ 1 antibody (clone E-12) were purchased from Santa Cruz Biotech (Santa Cruz, MA). Anti-phospho-PKC θ antibody (T538) and anti-GLK/MAP4K3 antibody were purchased from Cell Signaling (Beverly, MA). Anti- β -tubulin antibody was purchased from Upstate (Lake Placid, NY). HRP-conjugated rabbit-anti-mouse immunoglobulin and HRP-conjugated goat-anti-rabbit immunoglobulin were purchased from Amersham Bioscience (Buckinghamshire, UK). Anti-GLK/MAP4K3 antibody was derived from Dr. Tse-Hua Tan (National Health Research Institutes). Anti-HA antibody was derived from Dr. Soo-Chen Cheng (Academia Sinica).

2.3 Chemicals and reagents

Phenol chloroform and Polybrene were purchased from Calbiochem (Darmstadt, Germany). Phenylmethanyl sulfonyl fluoride (PMSF), 1,4-dithiothreitol (DTT) and β -Mercaptoethanol were purchased from Merck (Darmstadt, Germany). PVDF membrane was purchased from Millipore (Massachusetts, US). [32 P]phosphate was purchased from Amersham Bioscience (Buckinghamshire, UK). Maestrotectin transfection reagent was purchased from Omics Bio (Taipei, Taiwan). ECL reagent was purchased from Advanta (California, US). PageRuler pre-stained protein ladder and stripping buffer were purchased from Thermo (Rockford, US). Acrylamide/bis 30% solution (29:1) was purchased from Bio Basic Inc. (Ontario, Canada). Albumin, from



bovine serum was purchased from Sigma (Missouri, US). Protein G Mag Sepharose Xtrawas purchased from GE Healthcare (Uppsala, Sweden). Protein assay dye reagent concentrate was purchased from Bio-Rad (California, US).Ethanol, EDTA, glycerol and isopropanol were purchased from Mallinckrodt Baker Inc (New Jersey, US).Complete Protease Inhibitor Cocktail Tablet was purchased from Roche (Indianapolis, US).

2.4 Plasmid construction and preparation

2.4.1 Construction of pcDNA4-hPKC θ -6xHA

For over-expressing the human PKC θ -6xHA protein with the expression of HA tag, we subcloned humanPKC θ from pcDNA4-hPKC θ -mycto pcDNA4-6xHA vector.The pcDNA4-hPKC θ -mycand pcDNA4-6xHA were digested with XhoI and PmeI, and digested human PKC θ was subcloned into pcDNA4-6xHAvector to express pcDNA4-hPKC θ -6xHA.

2.4.2 Construction of pcDNA4-hMAP4K3/GLK-myc

For over-expressing the human MAP4K3/GLK protein in HEK293 T cell and Jurkat JE6.1 T cell, we purchased human pBluescriptR-MAP4K3/GLK clone from Transomic Technologies. pBluescriptR-MAP4K3/GLK and pcDNA4-mycwere

digested with XhoI and BamHI, and digested human MAP4K3/GLK and pcDNA4-myc vector were ligated to express pcDNA4-MAP4K3/GLK-myc.



2.4.3 Construction of pcDNA4-hMAP4K3/GLK-6xHA

For over-expressing the human MAP4K3/GLK-6xHA protein with the expression of HA tag, we subcloned human MAP4K3/GLK from pcDNA4-hMAP4K3/GLK-myc to pcDNA4-6xHA vector. The pcDNA4-hMAP4K3/GLK-myc and pcDNA4-6xHA were digested with XhoI and PmeI, and digested human MAP4K3/GLK was subcloned into pcDNA4-6xHA vector to express pcDNA4-hMAP4K3/GLK-6xHA.

2.4.4 Construction of truncated forms of human MAP4K3/GLK

Human MAP4K3/GLK-6xHA is composed of kinase domain, proline-rich repeats and CNH domain. All of the truncated forms were generated by PCR using Jurkat JE6.1 cDNA as a template. For kinase domain the sense primer (5'-AGGATCCATGAACCCCGGCTTCGATTTG-3') introduced a BamHI site, and an antisense primer (5'-TCTCGAGTACAAAAGGATGCTGTAATAA-3') introduced a XhoI site. For proline-rich repeats the sense primer (5'-AGGATCCATGACACAACATTTGACACGGTC-3') introduced a BamHI site,

and an antisense primer (5'-TCTCGAGTTTAGGTGTTGGAGGAAGAC-3') introduced a XhoI site. For C-terminal citron homology domain the sense primer (5'-AGGATCCATGGTGCATATGGGTGCATG-3') introduced a BamHI site, and an antisense primer (5'-TCTCGAGGTAAGTGTTCATGACCCG-3') introduced a XhoI site. Each amplified fragment was ligated into the BamHI and XhoI sites of pcDNA4-6xHA.

2.4.5 Construction of pcDNA4-hSLP-76-6xHA

Human SLP-76 was generated by PCR using Jurkat JE6.1 cDNA as a template. Sense primer (5'-AGGATCCATGGCACTGAGGAATGTGCCC-3') introduced a BamHI site, and antisense primer (5'-TCTCGAGTGGGTACCCTGCAGCATGCGTTA-3') introduced a XhoI site. Amplified fragment was ligated into the BamHI and XhoI sites of pcDNA4-6xHA.

2.4.6 Construction of kinase-dead form of human PKC θ

The kinase activity of human PKC θ is activated after the phosphorylation of Lys409. Kinase-dead K409A PKC θ was constructed from wild-type PKC θ by site-directed mutagenesis. Mutagenesis was performed with sense primer (5'-CAATTTTTCGCAATAGCGGCCTTAAAGAAAGATG) and antisense primer

(5'-CATCTTTCTTTAAGGCCGCTATTGCGAAAAATTG-3') by polymerase.



2.4.7 Construction of kinase-dead form of human MAP4K3/GLK


The kinase activity of human MAP4K3/GLK is activated after the phosphorylation of Lys45. Kinase-dead K45A MAP4K3/GLK was constructed from wild-type MAP4K3/GLK by site-directed mutagenesis. Mutagenesis was performed with sense primer (5'- GAATTAGCAGCAATTGCAGTAATAAAATTGGAAC) and antisense primer (5'-GTTCCAATTTTATTACTGCAATTGCTGCTAATTC-3') by polymerase.

2.5 Transfection of plasmid DNA

2.5.1 Calcium phosphate transfection

HEK293T cells were maintained to 80% confluent, and media were replaced on each plate with 8ml of completed DMEM. 10 μ g plasmid DNA was added into sterile ddH₂O in total volume of 450 μ l, and 50 μ l 2.5M CaCl₂ was added and mixed in each tube immediately. DNA/CaCl₂ mixture was slowly (drop-wise) added into 0.5 ml of 2x HBS with bubbling. Transfection mix was added to plates in drop-wise fashion, and mixed by rocking back and forth and put in 37°C, 5% CO₂ incubator. Media were changed the next day with fresh completed medium.

2.5.2 Retrovirus infection



HEK293T cells were transfected with pGC-YFP and pGC-DAPK-YFP by calcium phosphate transfection. After 24 hours, media were changed with 10% FBS RPMI-1640. After 48 hours, supernatant of HEK293T cells culture medium was collected, containing infective retrovirus particles. 5 µg/ml polybrene was added into supernatant. 1×10^6 Jurkat JE6.1 T cells were suspended with the supernatant, and were transferred into 6-well plate. Infected Jurkat JE6.1 T cells were centrifuged in 1650 rpm at room temperature for 45 minutes, then were incubated in 37°C, 5% CO₂ incubator for 48 hours.

2.5.3 Electroporation

8.8×10^6 EL4 T cell pellets were resuspended in 100 µl Neon™ R buffer, and were mixed with plasmid DNA. Adequate program of electroporator (Neon™) was chosen to transfect plasmids. Electroporated cells were resuspended with RPMI-1640 containing 10% FBS, then were incubated in 37°C, 5% CO₂ incubator for at least 24 hours before experimental analysis.

2.6 T cell activation

Jurkat JE6.1 T cells were activated in 6-well plate. 6-well plate was coated with

5 μ g/ml anti-CD3 and 2.5 μ g/ml anti-CD28 antibodies 16 hours before the activation.

Jurkat JE6.1 T cells were rested with 1% FBS-containing RPMI-1640 for 30 minutes, and were seeded into anti-CD3/anti-CD28-coated plate and cultured in the incubator at 37°C. Activated Jurkat JE6.1 T cells were collected at specific time point, and were lysed to perform western blotting.

2.7 Western Blotting

Protein samples were boiled for 5 minutes in SDS sample buffer (50 mM Tris-HCl pH 6.8, 5% glycerol, 2.5% β -Mercaptoethanol, 2% SDS, 0.0025% bromophenol blue), and were separated with 10% SDS-PAGE then transferred to nitrocellulose membrane. Membrane was blocked with 5% skim milk dissolved in TBST and was incubated with primary antibody at 4°C overnight. Secondary antibody was added on next day for 1 hr, and the signals were revealed by ECL.

2.8 Immunoprecipitation

Sample cells were collected and washed by PBS once and lysed with WCE lysis buffer. Cell lysates were immunoprecipitated with specific antibody swirling overnight, and were mixed with 20 μ l protein G magnetic beads for 1 hour at 4°C. Unbound antibodies were washed out with WCE buffer for 4 times. Protein G

magnetic beads with sample buffer were resuspended and boiled at 100°C for 10 min.

Cell lysates were collected to perform SDS-PAGE and western blotting.



2.9 Luciferase assay

pNF- κ B-Luc (App. 9) is the reporter of the analysis. There are five NF- κ B binding sites at the enhancer element before *luciferase* gene, and the luminescent enzyme is activated after the binding of NF- κ B.

pNF- κ B-Luc was transduced into EL4 T cells by electroporation. 24 hours after the transduction, EL4 T cells were activated with anti-CD3/anti-CD28, and were collected at specific time point. Collected cells were rinsed with PBS twice, and were lysed with CCLR (culture cell lysis reagent, 0.1 M K-phosphate pH 7.8, 0.1 mM EDTA, 10% glycerol, 1% Triton X-100, 7mM 2-mercaptoethanol). Lysed cells were vortexed for 5 minutes, and centrifuged in 14000rpm for 6 minutes at 4 °C. Supernatant was collected as cell extraction to perform the luciferase assay.

Fresh LAR (Luciferase assay reagent, 25 mM Tricine pH 7.8, 15mM K-phosphate pH 7.8, 15mM MgSO₄, 4mM EGTA, 2mM ATP, 1mM DTT) was prepared before performing the luciferase assay, and 180 μ l LAR was mixed with 50 μ l 0.2mM Luciferin. 50 μ l cell extraction was mixed with 200 μ l LAR/Luciferin mixture in 96-well plate. Analysis of the luminescent signal was performed with

Perkin Elmer Life Science VICTOR.



2.10 *In vitro* kinase assay

Recombinant proteins were incubated with kinase buffer, 1 μ M CaM, 0.5mM CaCl₂, 50 μ M cold ATP and 1 μ Ci γ ³²P-ATP at 25°C for 30 minutes. The reaction mixture was resolved by SDS-PAGE and the phosphorylation was determined by autoradiography. 1/10 volume of reaction mixture without γ ³²P-ATP was collected to perform SDS-PAGE and western blotting as loading control.

2.11 *In vitro* binding assay

Recombinant proteins were incubated with BSA at 4°C for 2 hours, and antibodies were added to incubate for 16 hours. The reaction mixture was resolved by SDS-PAGE and the binding quantity was determined by antibodies. 1/10 volume of reaction mixture was collected to perform SDS-PAGE and western blotting as loading control.

Chapter III Results



3.1 Establishment of Jurkat JE6.1 T cell line stably expressing DAPK

To study the role of DAPK in the NF- κ B pathway in T cells, we subcloned *dapk* gene into pGC-YFP vector. We transfected pGC-YFP and pGC-DAPK-YFP plasmids into 293 Phoenix cells for retrovirus package. After 72 hours, we collected the virus supernatant and infected Jurkat JE6.1 T cells to establish stable clone. 48~72 hours after virus infection, the YFP-expressing Jurkat JE6.1 T cells were sorted by FACS (Fig.1A). The DAPK expression in pGC-DAPK-YFP transduced JE6.1 cells was confirmed by Western blotting (Fig.1B).

3.2 DAPK inhibits TCR-stimulated NF- κ B activation

3.2.1 Expression of DAPK mutant forms affects the activation of NF- κ B reporter

Previous studies from our lab have shown that DAPK inhibits the TCR-induced NF- κ B activation [13]. To re-examine the effect of DAPK on NF- κ B activation, κ B-Luc was transfected with RK5F (vector only), DAPK-K42A (dominant negative form) or DAPK- Δ CaM (constitutively active form) into EL4 T cells by electroporation. EL4 cells were then stimulated by anti-CD3/anti-CD28 TCR stimulation, and the luciferase activity is determined 6 hours and 9 hours after activation. Result shows that TCR-induced κ B-Luc activity was enhanced by

DAPK-K42A and was inhibited by DAPK- Δ CaM (Fig.2).



3.2.2 DAPK suppresses TCR-induced phosphorylation of PKC θ


To further confirm the stage of TCR-induced NF- κ B pathway regulated by DAPK, control and DAPK-expressing Jurkat JE6.1 cells were activated by anti-CD3/anti-CD28. PKC θ and the phosphorylation of PKC θ at Thr538 were analyzed in control and Jurkat JE6.1 T cells stably expressing DAPK by Western blotting. Result shows that over-expression of DAPK decreased TCR-induced PKC θ phosphorylation (Fig. 3).

3.3 Interaction of DAPK with PKC θ

3.3.1 Immunoprecipitation analysis of DAPK and PKC θ

To determine how DAPK regulates the activation of PKC θ , we first investigated whether DAPK interacts with PKC θ . DAPK-FLAG and PKC θ -6xHA were transfected into HEK293T cells, cell lysates were immunoprecipitated with anti-FLAG or anti-HA, and the presence of DAPK-FLAG and PKC θ -6xHA were determined. Result shows that DAPK-FLAG was associated with PKC θ -6xHA in HEK293T after overexpression (Fig. 4). We also investigated whether DAPK interacts with PKC θ in T cells after TCR stimulation. pGC-DAPK-YFP-JE6.1 cells were activated by anti-CD3/anti-CD28, and the association of DAPK and endogenous PKC θ was

analyzed by immunoprecipitation. Result shows that DAPK interacted with endogenous PKC θ in Jurkat JE6.1 T cells, and the interaction was increased 15 minutes and 45 minutes after TCR stimulation (Fig. 5).



3.3.2 Determination of the interaction domains between DAPK and PKC θ

To determine which domain of DAPK is responsible for interacting with PKC θ , we transfected FLAG-tagged DAPK fragments with PKC θ -6xHA into HEK293T cells and performed immunoprecipitation analysis. Result shows that ankyrin repeats and death domain of DAPK were the regions on DAPK that interacted with PKC θ (Fig. 6).

We similarly transfected FLAG-tagged PKC θ fragments with DAPK-Myc into HEK293T cells to determine the DAPK-interacting domain of PKC θ . Result shows that both N-terminus and C-terminus of PKC θ interacted with DAPK (Fig. 7).

3.4 Interaction of DAPK with MAP4K3/GLK

3.4.1 Immunoprecipitation analysis of DAPK and MAP4K3/GLK


To determine whether DAPK regulates the activation of MAP4K3/GLK, we examined whether DAPK interacts with MAP4K3/GLK. After the transfection of DAPK-FLAG and MAP4K3/GLK-6xHA into HEK293T cells, cell lysates were immunoprecipitated with anti-FLAG or anti-HA, and the presence of DAPK-FLAG and MAP4K3/GLK-6xHA were examined. Result shows that DAPK-FLAG was

associated with MAP4K3/GLK-6xHA in HEK293T after over-expression (Fig. 8). We further investigated whether DAPK interacts with MAP4K3/GLK in T cells after TCR stimulation. Jurkat JE6.1 T cells stably expressing DAPK-FLAG were activated by anti-CD3/anti-CD28, and the association of DAPK and the endogenous MAP4K3/GLK was determined by immunoprecipitation with anti-FLAG. Result shows that DAPK interacted with endogenous MAP4K3/GLK in Jurkat JE6.1 T cells, and the interaction was enhanced 15 minutes after TCR stimulation (Fig. 9).

3.4.2 Determination of the interaction domains of DAPK and MAP4K3/GLK

To determine the domain of DAPK that is responsible for interacting with MAP4K3/GLK, we transfected FLAG-tagged DAPK fragments with MAP4K3/GLK-6xHA into HEK293T cells and performed immunoprecipitation analysis. Result shows that cytoskeleton binding domain and death domain of DAPK interacted with MAP4K3/GLK (Fig. 10). We further constructed 6xHA-tagged MAP4K3/GLK fragments containing kinase (K) domain, proline-rich repeats (PR) domain and C-terminal citron homology (CNH) domains of human MAP4K3/GLK. 6xHA-tagged MAP4K3/GLK fragments were transfected into HEK293T cells with DAPK-FLAG and immunoprecipitation with anti-HA was used to examine the DAPK-binding region of MAP4K3/GLK. Result shows that kinase domain of

MAP4K3/GLK was the DAPK-interacting domain on MAP4K3/GLK (Fig. 11).



3.5 To determine whether PKC θ or MAP4K3/GLK is the substrate of DAPK


3.5.1 Preparation of human PKC θ recombinant protein

Previous report has shown that DAPK-K42A (dominant negative form) promotes the activation of TCR-induced NF- κ B pathway[13]. We speculated that kinase activity of DAPK may play an important role in the inhibitory process. We subcloned human PKC θ into pET21a vector (App. 7), after transformation into *E. coli*; PKC θ expression was induced with 0.5mM IPTG. PKC θ recombinant protein was purified with anti-6xHis antibody-coated beads. Fig. 12 shows the quantity of human PKC θ recombinant protein compared with various concentration of BSA.

3.5.2 Preparation of human MAP4K3/GLK recombinant protein

We subcloned human MAP4K3/GLK into pcDNA4/6xHA vector (App. 8) and transfected into HEK293T cells. The human MAP4K3/GLK recombinant protein was purified from HEK293T cell lysates with anti-6xHA antibody-coated beads. Fig. 13 shows the quantity of human MAP4K3/GLK recombinant protein compared with various concentration of BSA.

3.5.3 Kinase assay performed with DAPK and PKC θ




We then investigated whether PKC θ is a direct substrate of DAPK. We incubated recombinant DAPK with PKC θ -6xHA and $\gamma^{32}\text{P}$ -ATP in kinase buffer at 25°C for 30 minutes. The reaction mixture was resolved by SDS-PAGE and the phosphorylation was determined by autoradiography. Result shows that the phosphorylation level of PKC θ was elevated in the presence of DAPK (Fig. 14). However, the auto-phosphorylation of PKC θ was detected in the *in vitro* kinase assay in the absence of DAPK. Hence we generated recombinant PKC θ -K409A, the kinase-dead PKC θ , to further examine the phosphorylation phenomenon.

3.5.4 Preparation of PKC θ and GLK kinase-dead recombinant proteins

We use site-direct mutagenesis to generate PKC θ -K409A and MAP4K3/GLK-K45A kinase-dead form plasmids. We subcloned PKC θ -K409A and MAP4K3/GLK-K45A into pcDNA4/6xHA vector (App. 8), and transfected into HEK293T cell. The PKC θ -K409A-6xHA and MAP4K3/GLK-K45A-6xHA recombinant proteins were purified with anti-6xHA antibody-coated beads. Fig. 15 shows the quantity of PKC θ -K409A-6xHA and MAP4K3/GLK-K45A-6xHA recombinant proteins compared with various concentration of BSA.

3.5.5 DAPK does not phosphorylates PKC θ *in vitro*



We incubated recombinant DAPK with PKC θ -K409A-6xHA and γ ³²P-ATP in kinase buffer at 25°C for 30 minutes. The reaction mixture was resolved by SDS-PAGE and the phosphorylation was determined by autoradiography. Result shows that DAPK did not phosphorylate PKC θ in contrast to DAPK-mediated phosphorylation of MLC (Fig. 16).

3.5.6 DAPK does not phosphorylate MAP4K3/GLK *in vitro*

We also incubated recombinant DAPK with MAP4K3/GLK-K45A-6xHA and γ ³²P-ATP in kinase buffer at 25°C for 30 minutes. The reaction mixture was resolved by SDS-PAGE and the phosphorylation was determined by autoradiography. Result shows that DAPK did not phosphorylate MAP4K3/GLK in contrast to DAPK-mediated phosphorylation of MLC (Fig. 17).

3.6 To determine whether DAPK affect the kinase activity of MAP4K3/GLK

Our results suggested that PKC θ and MAP4K3/GLK are not the direct kinase substrates of DAPK. We next examined whether DAPK affects the kinase activity of MAP4K3/GLK.

3.6.1 Kinase assay performed with MAP4K3/GLK and MBP


To determine whether MAP4K3/GLK kinase activity is affected by DAPK, we incubated recombinant MAP4K3/GLK-6xHA and its substrate myelin basic protein (MBP) with or without DAPK in kinase buffer and $\gamma^{32}\text{P}$ -ATP at 25°C for 30 minutes.

The reaction mixture was resolved by SDS-PAGE and the phosphorylation was determined by autoradiography. Result shows that the MAP4K3/GLK auto-phosphorylation and the phosphorylation of MBP were both diminished in the presence of DAPK, in a dose-dependent manner (Fig. 18), suggesting a possibility that DAPK inhibits the kinase activity of MAP4K3/GLK to MBP.

3.6.2 Preparation of human SLP-76 recombinant protein

Recent report has shown that the interaction between SLP-76 and MAP4K3/GLK is mediated through tyrosine phosphorylation of SLP-76[19]. Since GLK acts as a kinase, we investigated whether SLP-76 is one of the substrates of GLK. To analyze whether SLP-76 is direct substrate of GLK, human SLP-76 were subcloned into pcDNA4/6xHA vector (App. 8), and transfected into HEK293T cells. The human SLP-76 recombinant protein was purified with anti-6xHA antibody-coated beads. Fig. 19 shows the quantity of human SLP-76 recombinant protein compared with various concentration of BSA.

3.6.3 Kinase assay performed with MAP4K3/GLK and SLP-76



To determine whether MAP4K3/GLK directly phosphorylates SLP-76, we incubated recombinant MAP4K3/GLK-6xHA with SLP-76-6xHA and $\gamma^{32}\text{P}$ -ATP in kinase buffer at 25°C for 30 minutes. The reaction mixture was resolved by SDS-PAGE and the phosphorylation was determined by autoradiography. Result shows that MAP4K3/GLK directly phosphorylates SLP-76 (Fig. 20).

To determine whether the MAP4K3/GLK-mediated phosphorylation of SLP-76 is affected by DAPK, we incubated recombinant MAP4K3/GLK-6xHA and SLP-76-6xHA with or without DAPK in kinase buffer and $\gamma^{32}\text{P}$ -ATP at 25°C for 30 minutes. The reaction mixture was resolved by SDS-PAGE and the phosphorylation was determined by autoradiography. Result shows that the MAP4K3/GLK auto-phosphorylation and the phosphorylation of SLP-76 were both diminished in the presence of DAPK, in a dose-dependent manner (Fig. 20), suggesting a possibility that DAPK inhibits the kinase activity of MAP4K3/GLK to SLP-76.

3.7 To determine whether DAPK interferes with the association of MAP4K3/GLK and SLP-76

Previous report has shown that the association with SLP-76 is necessary for the activation of MAP4K3/GLK [19]. We examined another possibility that DAPK may inhibit the kinase activity by interfering with the binding of MAP4K3/GLK to

SLP-76.



3.7.1 DAPK interacts with SLP-76

To determine whether DAPK inhibits the association of MAP4K3/GLK and SLP-76, we examined whether DAPK interacts with SLP-76. After the transfection of DAPK-FLAG and SLP-76-6xHA into HEK293T cells, immunoprecipitation and immunoblot were used to analyze the association of DAPK-FLAG and SLP-76-6xHA in HEK293T cells. Result shows that DAPK-FLAG was associated with SLP-76-6xHA in HEK293T after overexpression (Fig. 21).


3.7.2 The endogenous MAP4K3/GLK-SLP-76 association is reduced by DAPK

To determine whether DAPK interferes with the association of the endogenous MAP4K3/GLK and SLP-76, control and DAPK-expressing Jurkat JE6.1 cells were activated by anti-CD3/anti-CD28, SLP-76 was immunoprecipitated and the presence of endogenous MAP4K3/GLK was determined. Result shows that the association of MAP4K3/GLK and SLP-76 was diminished in Jurkat JE6.1 T cell stably expressing DAPK (Fig. 22).

3.7.3 DAPK inhibits the *in vitro* binding between MAP4K3/GLK and SLP-76

To further investigate the effect of DAPK in the association of MAP4K3/GLK

and SLP-76, we used recombinant SLP-76-6xHA to perform the *in vitro* binding assay. MAP4K3/GLK-6xHA and SLP-76-6xHA were incubated with or without DAPK-FLAG in the binding buffer for 2 hours, and anti-SLP-76 antibody was used to capture the recombinant SLP-76. The reaction mixture was resolved by SDS-PAGE. Result shows that the presence of DAPK-FLAG inhibited the binding of MAP4K3/GLK-6xHA and SLP-76-6xHA *in vitro* (Fig. 23).



Chapter IV Discussion




In this study, we investigated how DAPK regulates the activation of PKC θ in TCR-induced NF- κ B activation. The expression of DAPK inhibited the NF- κ B activation in T cell after TCR stimulation (Fig.2), and DAPK specifically down-regulated the activation and phosphorylation of PKC θ after TCR stimulation (Fig. 3), similar to previous report from our lab[13].

4.1 DAPK is associated with SLP-76, MAP4K3/GLK, and PKC θ

After TCR stimulation, SLP-76 recruits MAP4K3/GLK and other molecules to form early T cell activation complex. MAP4K3/GLK then phosphorylates SLP-76, and becomes fully activated with enhanced binding to SLP-76. Activated MAP4K3/GLK phosphorylates PKC θ . We observed that DAPK interacted with SLP-76, MAP4K3/GLK, and PKC θ (Fig. 4, 5, 8, 9, 21), suggesting the possibility that DAPK may inhibit TCR-induced NF- κ B activation by its binding to molecules in the early T cell activation complex.

The interactions of DAPK with MAP4K3/GLK and PKC θ involve several domains on DAPK (Fig. 6, 7, 10, 11). Whether this suggests the presence of multiple routes for DAPK to inhibit TCR-induced NF- κ B activation, may deserve further exploration.

4.2 DAPK kinase activity and inhibition of NF- κ B activation




We observed that the expression of DAPK-K42A promotes NF- κ B activation and the expression of DAPK- Δ CaM inhibits the NF- κ B activation in T cell after TCR stimulation (Fig.2). These results suggest that the kinase activity of DAPK is involved in the down-regulation of TCR-induced NF- κ B. However, we found that DAPK did not phosphorylate MAP4K3/GLK and PKC θ (Fig. 16 and 17). Therefore, DAPK inhibits TCR-induced NF- κ B activation not through direct phosphorylation of GLK or PKC θ . Whether DAPK phosphorylates other molecules that lead to inactivation of NF- κ B remains to be determined.

4.3 DAPK inhibits the kinase activity of MAP4K3/GLK

Recent study illustrates that MAP4K3/GLK phosphorylates PKC θ after TCR engagement [19]. The auto-phosphorylation of MAP4K3/GLK at Ser170 is necessary for its kinase activity [26]. We observed that DAPK inhibits the auto-phosphorylation of MAP4K3/GLK (Fig. 18 and 20). By using myelin basic protein (MBP) as a substrate of MAP4K3/GLK in the *in vitro* kinase assay, we observed that the kinase activity of MAP4K3/GLK is reduced by the presence of increasing amounts of DAPK (Fig. 18).

SLP-76 recruits MAP4K3/GLK and other molecules to form complex after




TCR stimulation in T cell[19]. We found that MAP4K3/GLK directly phosphorylates SLP-76, and the SLP-76 phosphorylation by MAP4K3/GLK is decreased by DAPK in a dose dependent manner in *in vitro* kinase assay (Fig. 18). Together, these results suggest that DAPK directly interferes with MAP4K3/GLK kinase activity. To further examine the direct effect of DAPK on MAP4K3/GLK kinase activity, we will use DAPK mutants with reduced MAP4K3/GLK-binding to determine whether the inhibitory ability is proportional to the binding of DAPK to MAP4K3/GLK.

4.4 DAPK inhibits the association of MAP4K3/GLK and SLP-76

MAP4K3/GLK is recruited by SLP-76 after TCR stimulation in T cell, the association with SLP-76 is required for fully activation of MAP4K3/GLK [19]. To further investigate the role of DAPK in the TCR-induced NF- κ B activation, we examined the possibility that DAPK may physically interfere with the association of SLP-76 and MAP4K3/GLK.


We observed that the interaction of SLP-76 and MAP4K3/GLK was increased after anti-CD3/anti-CD28 activation in pGC-YFP Jurkat JE6.1 T cell. However, the enhanced SLP-76-MAP4K3/GLK association was inhibited in the pGC-DAPK-YFP Jurkat JE6.1 T cell (Fig. 22). This result suggests that over-expression of DAPK interferes with TCR-induced association of SLP-76 and MAP4K3/GLK.



We next examined that if the association of SLP-76 and MAP4K3/GLK is affected by DAPK in cell-free system. In *in vitro* binding assay, we observed that the interaction of SLP-76 and MAP4K3/GLK was blocked by the presence of increased amount of DAPK (Fig. 23). The results further validate that DAPK physically interferes with the association of SLP-76 and MAP4K3/GLK.

In summary, we confirmed that DAPK inhibits the TCR-induced NF- κ B activation. DAPK specifically inhibits the PKC θ phosphorylation downstream of TCR ligation. We identified at least two possible different mechanisms for DAPK to inhibit PKC θ phosphorylation stimulated by TCR. DAPK inhibits the kinase activity of MAP4K3/GLK on MBP and SLP-76 (Fig. 24A). DAPK blocks the association of SLP-76 and MAP4K3/GLK, which prevents the fully activation of MAP4K3/GLK (Fig. 24B). Future experiments are required to fully validate these two inhibitory processes by DAPK. There remains the possibility that DAPK may inhibit TCR-induced PKC θ activation through additional mechanism. Further investigation may help to identify these suppressive pathways mediated by DAPK.

Chapter V Reference




1. Deiss, L.P., et al., Identification of a novel serine/threonine kinase and a novel 15-kD protein as potential mediators of the gamma interferon-induced cell death. *Genes Dev*, 1995. **9**(1): p. 15-30.
2. Shani, G., et al., Autophosphorylation restrains the apoptotic activity of DRP-1 kinase by controlling dimerization and calmodulin binding. *EMBO J*, 2001. **20**(5): p. 1099-113.
3. Shohat, G., et al., The pro-apoptotic function of death-associated protein kinase is controlled by a unique inhibitory autophosphorylation-based mechanism. *J Biol Chem*, 2001. **276**(50): p. 47460-7.
4. Cohen, O., E. Feinstein, and A. Kimchi, DAP-kinase is a Ca²⁺/calmodulin-dependent, cytoskeletal-associated protein kinase, with cell death-inducing functions that depend on its catalytic activity. *EMBO J*, 1997. **16**(5): p. 998-1008.
5. Lin, J. and A. Weiss, T cell receptor signalling. *J Cell Sci*, 2001. **114**(Pt 2): p. 243-4.
6. Reth, M., Antigen receptor tail clue. *Nature*, 1989. **338**(6214): p. 383-4.
7. Chu, D.H., C.T. Morita, and A. Weiss, The Syk family of protein tyrosine kinases in T-cell activation and development. *Immunol Rev*, 1998. **165**: p. 167-80.
8. Wonerow, P. and S.P. Watson, The transmembrane adapter LAT plays a central role in immune receptor signalling. *Oncogene*, 2001. **20**(44): p. 6273-83.
9. Samelson, L.E., Signal transduction mediated by the T cell antigen receptor: the role of adapter proteins. *Annu Rev Immunol*, 2002. **20**: p. 371-94.
10. Imboden, J.B. and J.D. Stobo, Transmembrane signalling by the T cell antigen receptor. Perturbation of the T3-antigen receptor complex generates inositol phosphates and releases calcium ions from intracellular stores. *J Exp Med*, 1985. **161**(3): p. 446-56.
11. Werlen, G., et al., Calcineurin preferentially synergizes with PKC-theta to activate JNK and IL-2 promoter in T lymphocytes. *EMBO J*, 1998. **17**(11): p. 3101-11.
12. Ghaffari-Tabrizi, N., et al., Protein kinase Ctheta, a selective upstream regulator of JNK/SAPK and IL-2 promoter activation in Jurkat T cells. *Eur J Immunol*, 1999. **29**(1): p. 132-42.
13. Chuang, Y.T., et al., The tumor suppressor death-associated protein kinase targets to TCR-stimulated NF-kappa B activation. *J Immunol*, 2008. **180**(5): p.

- 3238-49.
14. Koretzky, G.A., F. Abtahian, and M.A. Silverman, SLP76 and SLP65: complex regulation of signalling in lymphocytes and beyond. *Nat Rev Immunol*, 2006. **6**(1): p. 67-78.
 15. Wu, J., et al., Vav and SLP-76 interact and functionally cooperate in IL-2 gene activation. *Immunity*, 1996. **4**(6): p. 593-602.
 16. Wunderlich, L., et al., Association of Nck with tyrosine-phosphorylated SLP-76 in activated T lymphocytes. *Eur J Immunol*, 1999. **29**(4): p. 1068-75.
 17. Bunnell, S.C., et al., Biochemical interactions integrating Itk with the T cell receptor-initiated signaling cascade. *J Biol Chem*, 2000. **275**(3): p. 2219-30.
 18. Kumar, L., et al., Differential role of SLP-76 domains in T cell development and function. *Proc Natl Acad Sci U S A*, 2002. **99**(2): p. 884-9.
 19. Chuang, H.C., et al., The kinase GLK controls autoimmunity and NF-kappaB signaling by activating the kinase PKC-theta in T cells. *Nat Immunol*, 2011. **12**(11): p. 1113-8.
 20. Resnik-Docampo, M. and J.F. de Celis, MAP4K3 is a component of the TORC1 signalling complex that modulates cell growth and viability in *Drosophila melanogaster*. *PLoS One*, 2011. **6**(1): p. e14528.
 21. Chen, D.Y., et al., Germinal center kinase-like kinase (GLK/MAP4K3) expression is increased in adult-onset Still's disease and may act as an activity marker. *BMC Med*, 2012. **10**: p. 84.
 22. Mellor, H. and P.J. Parker, The extended protein kinase C superfamily. *Biochem J*, 1998. **332** (Pt 2): p. 281-92.
 23. Nishizuka, Y., Protein kinase C and lipid signaling for sustained cellular responses. *FASEB J*, 1995. **9**(7): p. 484-96.
 24. Altman, A., N. Isakov, and G. Baier, Protein kinase Ctheta: a new essential superstar on the T-cell stage. *Immunol Today*, 2000. **21**(11): p. 567-73.
 25. Li, Q. and I.M. Verma, NF-kappaB regulation in the immune system. *Nat Rev Immunol*, 2002. **2**(10): p. 725-34.
 26. Yan, L., et al., PP2A T61 epsilon is an inhibitor of MAP4K3 in nutrient signaling to mTOR. *Mol Cell*, 2010. **37**(5): p. 633-42.

Chapter VI Figures



A



B




Figure 1. Over-express DAPK in Jurkat JE6.1 T cell

pGC-YFP or pGC-DAPK-YFP was transfected into 293 Phoenix cells for virus package. Virus supernatant was collected to infect Jurkat JE6.1 T cells. Jurkat JE6.1 T cells transduced with pGC-YFP or pGC-DAPK-YFP were sorted by YFP expression on FACS. The purity of YFP-expressing Jurkat JE6.1 T cells is as shown by FACS analysis (A). (B) Cells from A were lysed and the expression of DAPK-FLAG is determined by Western blotting.




Figure 2. DAPK inhibits TCR-stimulated NF-κB activation

TCR-induced NF-κB pathway was increased by DAPK-K42A and inhibited by DAPK-ΔCaM. EL4 T cells were transfected with κB-Luc togetherwith RK5F (vector only), DAPK-K42A (dominant negative form) or DAPK-ΔCaM (constitutively active form).One day after transfection, EL4 cells were activated by anti-CD3/anti-CD28, and luciferase activity is determined at 6, 9 hours after stimulation.*** $P < 0.001$ for paired t test.




Figure 3. DAPK inhibits TCR-stimulated PKCθ phosphorylation

Over-expression of DAPK decreases TCR-induced PKCθ phosphorylation. Control and DAPK-overexpression Jurkat JE6.1 T cells were activated by anti-CD3/anti-CD8, and the contents of DAPK, PKCθ, p-PKCθ were determined by immunoblot. The extent of p-PKCθ induction was quantified by densitometry and normalized by PKCθ levels.




Figure 4. Interaction of DAPK with PKCθ in HEK 293T cell

HEK293T cells were transfected with DAPK-FLAG and PKCθ-6xHA as indication. Cell lysates were prepared 48 hours later, and were precipitated with anti-FLAG or anti-HA. The presence of DAPK and PKCθ was detected by anti-FLAG and anti-HA respectively.




Figure 5. Interaction of DAPK with PKC θ in Jurkat JE6.1 T cell

Jurkat JE6.1 T cell expressing DAPK-FLAG (Fig.1) were activated by anti-CD3/anti-CD28, and cell lysates were prepared at the indicated time points. Cell lysates were precipitated with anti-FLAG, and the presence of PKC θ was determined by anti-PKC θ . Input indicates the levels of DAPK-FLAG, PKC θ and p-PKC θ (T538) in cell lysates.




Figure 6. The interaction between DAPK and PKCθ is mediated by multiple domains.

HEK293T cells were transfected with Flag-tagged DAPK fragments containing kinase domain (K), calcium/calmodulin regulatory domain (CaM), ankyrin repeats domain (AR), cytoskeleton binding domain (Cy), linking domain (Li), or death domain (DD) (App. 1), in addition to PKCθ-6xHA. Cell lysates were prepared 48 hours later, and were immunoprecipitated with anti-HA, the presences of DAPK fragments were detected by anti-FLAG. Input indicates the contents of PKCθ-HA and DAPK fragments in cell lysates.




Figure 7. The interaction between PKCθ and DAPK is mediated by multiple domains.

HEK293T cells were transfected with Flag-tagged PKCθ fragments containing kinase-deletion domain (N-terminus) and kinase domain (C-terminus) (App. 3), in addition to DAPK-myc. Cell lysates were prepared 48 hours later, and were immunoprecipitated with anti-myc. The presences of PKCθ fragments were detected by anti-FLAG. Input indicates the contents of DAPK-myc and PKCθ fragments in cell lysates.




Figure 8. Interaction of DAPK with MAP4K3/GLK in HEK 293T cell
HEK293T cells were transfected with DAPK-FLAG and MAP4K3/GLK-6xHA as indication. Cell lysates were prepared 48 hours later, and were precipitated with anti-FLAG or anti-HA. The presence of DAPK and MAP4K3/GLK was detected by anti-FLAG and anti-HA respectively.




Figure 9. Interaction of DAPK with MAP4K3/GLK in Jurkat JE6.1 T cell

Jurkat JE6.1 T cell expressing DAPK-FLAG (Fig.1) were activated by anti-CD3/anti-CD28, and cell lysates were prepared at the indicated time points. Cell lysates were precipitated with anti-FLAG, and the presence of MAP4K3/GLK was determined by anti-GLK. Input indicates the levels of DAPK-FLAG and MAP4K3/GLK in cell lysates.




Figure 10. The interaction between DAPK and MAP4K3/GLK is mediated by multiple domains.

HEK293T cells were transfected with Flag-tagged DAPK fragments containing kinase domain (K), calcium/calmodulin regulatory domain (CaM), ankyrin repeats domain (AR), cytoskeleton binding domain (Cy), linking domain (Li), or death domain (DD) (App. 1), in addition to MAP4K3/GLK-6xHA. Cell lysates were prepared 48 hours later, and were immunoprecipitated with anti-HA. The presences of DAPK fragments were detected by anti-FLAG. Input indicates the contents of GLK-HA and DAPK fragments in cell lysates.




Figure 11. The interaction between MAP4K3/GLK and DAPK is mediated by multiple domains.

HEK293T cells were transfected with HA-tagged MAP4K3/GLK fragments containing kinase domain (KD) and proline-rich domain (PR)(App. 4) in addition to DAPK-FLAG. Cell lysates were prepared 48 hours later, and were immunoprecipitated with anti-HA. The presences of DAPK were detected by anti-FLAG. Input indicates the contents of DAPK-FLAG and MAP4K3/GLK fragments in cell lysates.




Figure 12. Generation of the recombinant protein of PKCθ

The recombinant PKCθ protein was purified with anti-6xHis antibody coated beads.




Figure 13. Generation of the recombinant protein of MAP4K3/GLK

The recombinant MAP4K3/GLK protein was purified from cell lysate by anti-6xHA antibody coated beads.




Figure 14. Auto-phosphorylation of PKC θ

Recombinant DAPK was incubated with PKC θ -6xHis in kinase buffer and $\gamma^{32}\text{P}$ -ATP. The kinase reaction was proceeded for 30 minutes at 25°C. The reaction mixture was resolved by SDS-PAGE and the phosphorylation was determined by autoradiography.




Figure 15. Generation of the kinase-dead recombinant protein of MAP4K3/GLK and PKCθ

The kinase-dead recombinant protein of MAP4K3/GLK and PKCθ were purified from cell lysate by anti-6xHA antibody coated beads.




Figure 16. PKC θ is not a substrate of DAPK.

Recombinant DAPK was incubated with PKC θ -K409A-6xHA or myosin light chain (MLC) in kinase buffer and γ ³²P-ATP. The kinase reaction was proceeded for 30 minutes at 25 °C . The reaction mixture was resolved by SDS-PAGE and the phosphorylation was determined by autoradiography. The Western blotting of the reaction mixture was used as loading control. The quantity of DAPK was detected by anti-FLAG, and the quantity of PKC θ is detected by anti-HA, and the quantity of MLC is detected by anti-GST.




Figure 17. MAP4K3/GLK is not a substrate of DAPK.

Recombinant DAPK was incubated with MAP4K3/GLK-K45A-6xHA or myosin light chain (MLC) in kinase buffer and $\gamma^{32}\text{P}$ -ATP. The kinase reaction was proceeded for 30 minutes at 25°C. The reaction mixture was resolved by SDS-PAGE and the phosphorylation was determined by autoradiography. The Western blotting of the reaction mixture was used as loading control. The quantity of DAPK was detected by anti-FLAG, and the quantity of MAP4K3/GLK is detected by anti-HA, and the quantity of MLC is detected by anti-GST.




Figure 18. The presence of DAPK reduces the kinase activity of MAP4K3/GLK

Recombinant MAP4K3/GLK-6xHA and myelin basic protein (MBP) were incubated with 0 μg , 0.3 μg or 1 μg DAPK in kinase buffer and $\gamma^{32}\text{P}$ -ATP at 25 $^{\circ}\text{C}$ for 30 minutes. The reaction mixture was resolved by SDS-PAGE and the phosphorylation was determined by autoradiography. The quantity of DAPK was detected by anti-FLAG, and the quantity of MAP4K3/GLK is detected by anti-HA, and the quantity of MBP is detected by anti-MBP.




Figure 19. Generation of the recombinant protein of SLP-76

The recombinant SLP-76 protein was purified from cell lysate by anti-6xHA antibody coated beads.




Figure 20. The presence of DAPK reduces the kinase activity of MAP4K3/GLK.

Recombinant MAP4K3/GLK-6xHA and SLP-76-6xHA were incubated with 0 μg , 0.3 μg or 1 μg DAPK in kinase buffer and $\gamma^{32}\text{P}$ -ATP at 25 $^{\circ}\text{C}$ for 30 minutes. The reaction mixture was resolved by SDS-PAGE and the phosphorylation was determined by autoradiography. The quantity of DAPK was detected by anti-FLAG, and the quantity of MAP4K3/GLK and SLP-76 are detected by anti-HA.




Figure 21. Interaction of DAPK with SLP-76

HEK293T cells were transfected with DAPK-FLAG and SLP-76-6xHA as indication. Cell lysates were prepared 48 hours later, and were precipitated with anti-FLAG or anti-HA. The presence of DAPK and SLP-76 was detected by anti-FLAG and anti-HA respectively.




Figure 22. The association of MAP4K3/GLK and SLP-76 is attenuated by DAPK in Jurkat JE6.1 T cells.

Control and DAPK-overexpression Jurkat JE6.1 T cells (Fig. 1) were activated by anti-CD3/anti-CD28, and cell lysates were prepared at the indicated time points. Cell lysates were precipitated with anti-SLP-76. The presence of MAP4K3/GLK was determined by anti-GLK, and the presence of SLP-76 was determined by anti-SLP-76. Total cell lysate indicates the levels of DAPK, MAP4K3/GLK, and SLP-76 in cell lysates, and the contents of DAPK, MAP4K3/GLK, and SLP-76 were determined by immunoblot.




Figure 23. The association of MAP4K3/GLK and SLP-76 is inhibited by DAPK *in vitro*.

Recombinant MAP4K3/GLK-6xHA and SLP-76-6xHA were incubated with or without the presence of recombinant DAPK-FLAG in binding buffer. The reaction mixture was incubated for 2 hours at 4°C, and anti-SLP-76 antibody was added to incubate for 16 hours. The reaction mixture was resolved by SDS-PAGE. Input indicates the levels of DAPK-FLAG, MAP4K3/GLK-6xHA, and SLP-76-6xHA in the reaction mixture, and the contents of DAPK-FLAG, MAP4K3/GLK-6xHA, and SLP-76-6xHA were determined by immunoblot.





Figure 24. Model on DAPK-mediated inhibition of PKC θ activation

Results from this study suggest two different mechanisms that DAPK inhibits TCR-induced PKC θ activation. First, DAPK inhibits the kinase activity of MAP4K3/GLK (A), second, DAPK blocks the association of SLP-76 and MAP4K3/GLK, which prevents the fully activation of MAP4K3/GLK (B).


Chapter VII Appendix



Appendix 1. DAPK protein structure

DAPK is protein composed of multiple domains. Kinase domain locates at the N-terminus, and following with a CaM-regulated domain, eight ankyrin repeats, two P-loop motifs, a cytoskeleton domain, and a death domain.


(From FEBS J. 2010 Jan;277(1):48-57)



Appendix 2. DAPK family


DAPK family is composed of death associated protein kinase (DAPK), death associated protein kinase related protein 1/ death associated protein kinase 2 (DRP-1/ DAPK2), DAP like kinase/ Zipper interacting protein kinase (Dlk/ ZIP-kinase), DAP kinase related apoptosis inducing protein kinase 1 (DRAK1), and DAP kinase related apoptosis inducing protein kinase 2. The sequence consistent among the five members is limited in the kinase domain located at N terminus.

(From Annu Rev Biochem. 2006;75:189-210)




Appendix 3. PKC θ protein structure

PKC θ is a protein composed of multiple domains. C2 domain locates at the N-terminus, and following with C1a domain, C1b domain, V3 domain, and the kinase domain locates at the C-terminus.



Appendix 4. MAP4K3/GLK protein structure


MAP4K3/GLK is a protein composed of multiple domains. Kinase domain locates at the N-terminus, and following with three proline-rich domains and a C-terminal citron homology domain.



Appendix 5. Signal transduction of TCR-induced T cell activation

The stimulation of cell surface receptors TCR and CD28 induces the activation of Ca^{2+} cation, PKC and Ras, which consequently activates transcriptional factors NF- κ B, NFAT and AP-1. Then the *il2* gene expression is driven and the production of IL-2 is promoted.


(From Nat Rev Immunol. 2007 Aug;7(8):599-609)



Appendix 6. NF-κB pathway

There are three distinct pathways to activate NF-κB pathway in T cells. The activation of TCR stimulates the activation of PKCθ, and the signal is transduced to Bcl-10, MALT1 and CARMA1 complex, and then the downstream IKK complex is activated consequently. Activated TNF receptor recruits TRADD, and binds to TRAF2 to transduce signals to RIP, which result in the activation of IKK. Activated IL-1 receptor or TLRs recruits MyD88, and MyD88 binds to IRAK. Activated IRAK phosphorylates TRAF6, and transduces signals to TAK-1, TAB-1, and TAB-2, and then activates the IKK complex. Activated IKK complex phosphorylates IκBα, and leads to the activation of NF-κB.


(From Nature. 2009 Mar 26;458(7237):430-7)



Appendix 7. Diagram of GLK-induced PKC θ /NF- κ B activation during TCR signaling

After TCR stimulation, activated Lck is recruited to TCR complex and phosphorylates ITAMs of CD3, resulting in Zap70 recruitment and activation. Zap70 activation induces the assembly of the proximal SLP-76 signaling complex. SLP-76 directly interacts with GLK and is required for GLK kinase activation. The activated GLK directly interacts with and phosphorylates PKC θ at Ter538, resulting in PKC θ membrane translocation and kinase activation. The activated PKC θ binds to and phosphorylates the signaling scaffold protein CARMA1, resulting in the activation of CARMA1 and the subsequent assembly of CARMA1-BCL10-MALT1 (CBM) complex. The CBM complex in turn induces the activation of the IKK/NF- κ B signaling cascade.


(From Nat Immunol. 2011 Oct 9;12(11):1113-8)




Appendix 8. pET-21a map



pcDNA4/6xHA Vector



Appendix 9. pcDNA4/6xHA map



Appendix 10. κ B-Luc schematic diagram

enhancer element : 5x (TGGGGACTTTCGC)

(From PathDetect in Vivo signal transduction pathway *cis*-reporting system instruction manual, Agilent technologies)